[{"id":"79ef0e88-111d-46b4-b454-13193bb2c7c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05002868","created_at":"2021-08-12T13:54:30.231Z","updated_at":"2024-07-02T16:35:05.010Z","phase":"Phase 1","brief_title":"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors","source_id_and_acronym":"NCT05002868","lead_sponsor":"Rhizen Pharmaceuticals SA","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RP12146"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 04/25/2024","primary_completion_date":" 04/25/2024","study_txt":" Completion: 04/25/2024","study_completion_date":" 04/25/2024","last_update_posted":"2024-05-08"}]